Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Replagal Advisory Committee Will Include Closed Door Session On Manufacturing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.

Advertisement

Related Content

Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated
Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated
Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification
Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed
TKT Replagal Surrogate Data Should Be Reworked For Accelerated Approval
Genzyme/TKT Fabry Agents Receive Co-Exclusive Orphan Drug Status In EU

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel